Phase 2
Completed N=42
Buspirone, Stress, and Attentional Bias to Marijuana Cues
Source: ClinicalTrials.gov NCT02132832 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements — 0.5795019; 0.5539831 ratio of errors (see OM description)
Summary
This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is to attenuate the influence of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone.
Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements |
0.5503957; 0.531073 | — |
| PRIMARY Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements |
0.5503957; 0.531073 | — |
| PRIMARY Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements |
0.5503957; 0.531073 | — |
| PRIMARY Stress as Assessed by the Perceived Stress Scale |
10.38889; 14.05263 | — |
| PRIMARY Stress as Assessed by the Perceived Stress Scale |
10.38889; 14.05263 | — |
| PRIMARY Stress as Assessed by the Perceived Stress Scale |
10.38889; 14.05263 | — |
| PRIMARY Anxiety as Assessed by the Zung Self-Rated Anxiety Scale |
33.27778; 31.63158 | — |
| PRIMARY Anxiety as Assessed by the Zung Self-Rated Anxiety Scale |
33.27778; 31.63158 | — |
| PRIMARY Anxiety as Assessed by the Zung Self-Rated Anxiety Scale |
33.27778; 31.63158 | — |
| PRIMARY Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) |
1.944444; 2.526316 | — |
| PRIMARY Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) |
1.944444; 2.526316 | — |
| PRIMARY Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) |
1.944444; 2.526316 | — |
Eligibility Criteria
Inclusion Criteria
- Marijuana substance use disorder based on a score of ≥ 13 on the Cannabis Use Disorders Identification Test - Revised (CUDIT-R)
- a score of ≥ 4 on the Cannabis Abuse Screening Test (CAST)
- meeting criteria for a marijuana substance use disorder based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)
Exclusion Criteria
- Current DSM-IV Axis I disorder other than marijuana use disorder
- serious medical illness requiring ongoing medical treatment, which could affect the central nervous system, or any other medical contraindication (e.g., renal, cardiovascular, pulmonary, blood) as determined by medical screening
- a positive pregnancy test or breast feeding (females)
- concomitant use of prescription medications that could affect the central nervous system
- active suicidal ideation or Beck Depression Inventory II score greater than 19
- positive urine drug screen for drugs other than marijuana or positive breath alcohol screen
- Shipley-2 test of cognitive aptitude score outside 2 SD units of the published composite score average
- smoking > 10 nicotine cigarettes per day / Fagerstrom Score > 4
- taking meds known to have significant drug interactions with buspirone.
Data sourced from ClinicalTrials.gov (NCT02132832). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.